1 / 16

Umbilical Cord Blood: An Alternate Source of Stem Cells

Umbilical Cord Blood: An Alternate Source of Stem Cells. Susan Parker Advisor: David Fahringer PA-C University of Kentucky College of Health Sciences Physician Assistant Program. Objectives. Understand the process of stem cell transplants Discuss methods of retrieval of stem cells

maleah
Download Presentation

Umbilical Cord Blood: An Alternate Source of Stem Cells

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Umbilical Cord Blood: An Alternate Source of Stem Cells Susan Parker Advisor: David Fahringer PA-C University of Kentucky College of Health Sciences Physician Assistant Program

  2. Objectives • Understand the process of stem cell transplants • Discuss methods of retrieval of stem cells • Learn benefits and disadvantages of using umbilical cord stem cells • Discuss ethical concerns surrounding umbilical cord blood use

  3. Stem Cell Transplants • Stem cell transplants are indicated for hematopoietic malignancies, bone marrow failure syndromes, and genetic immunodifiecient disorders. • When a patient needs a stem cell transplant, a suitable donor must be found. • Immune ablation, to reduce GVHD risk, is administered under intense medical supervision in a sterile environment. • The patient’s recovery begins with an extremely weak and vulnerable immune system with a wide range of complications and opportunistic infection risk.

  4. Stem Cell Transplants (cont’d) • 6 human leukocyte antigens (HLAs) need to be matched between donor and recipient to improve post-transplant prognosis • Only 30% of patients will have the ideal situation: related donor with all six HLA matches • If no suitable related donor, the process of searching the National Marrow Donor Program (NMDP) begins. • Currently, there are two sources of stem cells available to patients, bone marrow derived and umbilical cord derived stem cells.

  5. Your Chances of Finding a Donor • 10 million registered BM donors worldwide • Caucasion has a 50% chance of finding a donor • Minorities are lower, donor programs targeting subpopulations to increase diversity of donor pool. • Basically, <50% chance of finding a donor under any circumstance.

  6. Bone Marrow Stem Cells • Standard stem cell source for over 40 years • Obtained by bone marrow aspiration of the pelvis of donor • Relatively no risk to donor other than pain (no anesthetics used) • From beginning search to actual transplant takes 3-5 months

  7. Umbilical Cord Stem Cells • First successful transplant in 1988 • Relatively low risk to mother and baby • Beginning search to transplant in as few as 21 days

  8. Umbilical Cord Collection • Collected after delivery of baby, before delivery of placenta • Contraindicated in moderate-high risk births • Collected under aseptic techniques and stored at -80F

  9. Umbilical Cord Retrieval

  10. Benefits of UCSC over BMSC • Decreased transplant time • No chance of donor having acquired disease, infection, nor the possibility of donor declining procedure • Increased diversity of donor pool, much higher rates of minority donation • UCSC have acceptable mortality rates with 4/6 HLA matches • Faster neutrophil engraftment (lower chance of engraftment) • Best prognoses seen in pediatric patients • Non-myeloblative immune destruction has better outcome with UCSC transplant

  11. Drawbacks of UCSC • Longer time to immune system recovery due to immaturity of cells • Leads to increased GVHD and infection risk (but diseases less severe than with BM) • Less effective for adults • Cell dose of one sample usually inadequate for patients with increased body mass • Possible unknown genetic conditions of newborn donor

  12. The Bottom Line • Chance of engraftment similar between BM and UC • Decreased severity of complications with UC • Pooling of two or more UC samples has promising results, ex-vivo expansion of cells being researched • Collecting cord blood has variable results due to technique and delivery complications • Best outcome is still with 6/6 HLA matched related bone marrow donor • UC contains mesenchymal stem cells that have shown promise in becoming various types of tissues: neural, cardiac, hepatic, renal, etc.

  13. Ethics of Using UCSC • Alturistic donation – no cost to donor, increased attention to minorities, LOTS of paperwork and stipulations • Private donation - $1500 + $150/month with no guarantee of successful collection or storage • Recommendations for families with known genetic and inherited disorders • Pressure on families during an already stressful life event • Targeting middle and upper class mothers and obstetricians in wealthy areas • Not available to all women in all areas

  14. Private Cord Banking: Advertisement • http://www.cryo-cell.com/video_center/angelvision/index.asp

  15. References • Armson, 2005, B. Umbilical Cord Banking: Implications for Perinatal Providers. J Obstet Gynaecol Can. 2005 March; 27(3):263-90. • Ballen, 2005, K. New trends in umbilical cord blood transplantation. Blood. 2005 May; 105(10): 3786-91 • Barker, 2003, J., Weisdorf, D., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003 September; 102(5): 1915-19. • Bieback, 2004, K., Kern, S., Kluter, H., Eichler, H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells. 2004; 22: 625-634. • Fisk, 2005, N., Roberts, I., Markwald, R., Mironov, V. Can Routine Commercial Cord Blood Banking Be Scientifically and Ethically Justified? PloS Medicine. 2005 February; 2(2): 44- 47. • Laughlin, 2005, M., Giralt, S., Spitzer, T. Umbilical Cord Blood Transplantation: A New Alternative Option. Hematology. 2005; 377-383. • Lu, L., Yang, S., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with Hematopoiesis-supportive function and other potentials. The Hematology Journ. 2006; 91(8):1017-26. • O’Brien, 2006, T., Tiedemann, K., Vowels, M. No longer a biological waste product: umbilical cord blood. MJA. 2006 April; 184(8): 407-410. • Tuch, 2006, B. Stem Cells: A Clinical Update. Family Physician. 2006; 35: 719-721. • Wang, 2005, F., Huang, X., Zhang, Y., Chen, Y., Lu, D. Successful transplantation of double unit umbilical-cord blood from unrelated donors in high risk leukemia with a long follow-up. Chinese Medical Journal. 2005; 188(9): 772-6.

More Related